ADC Therapeutics S.A. is a biotechnology company focused on developing antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its primary revenue source comes from the sale of ZYNLONTA, with additional potential revenue from the ongoing development of other ADCs such as camidanlumab tesirine and ADCT-602. The company pursues partnerships with established pharmaceutical companies to support development and commercialization. The business faces high R&D costs, clinical trial risk, and regulatory uncertainty that can affect timelines and profitability.
—
ADC Therapeutics S.A. is a biotechnology company focused on developing antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its primary revenue source comes from the sale of ZYNLONTA, with additional potential revenue from the ongoing development of other ADCs such as camidanlumab tesirine and ADCT-602. The company pursues partnerships with established pharmaceutical companies to support development and commercialization. The business faces high R&D costs, clinical trial risk, and regulatory uncertainty that can affect timelines and profitability.
—
Daily adjusted close
ADC Therapeutics S.A. is a biotechnology company focused on developing antibody-drug conjugates (ADCs) for hematologic malignancies and solid tumors. Its primary revenue source comes from the sale of ZYNLONTA, with additional potential revenue from the ongoing development of other ADCs such as camidanlumab tesirine and ADCT-602. The company pursues partnerships with established pharmaceutical companies to support development and commercialization. The business faces high R&D costs, clinical trial risk, and regulatory uncertainty that can affect timelines and profitability.